51萝莉

Poster presentation with Novadiscovery at the ICSB 2018

Published on 31/10/2018

51萝莉 is pleased to collaborate with which is presenting at the ISCB today a poster titled 鈥淎 logical modelling approach to prepare and accelerate the design of ODE models: Application to bile acid metabolism鈥�. The model of bile acids metabolism was developed in the context of a project for 51萝莉, where the aim was to model chronic hepatitis B virus and non-alcoholic steatohepatitis (NASH).

Read next in 'Latest news'

• Enrollment completed for our Phase 2 clinical trial in Alport syndrome
• The first patient dosed in the Phase 2 ALPESTRIA-1 clinical study of Vonafexor for Alport syndrome
• The Phase 2 ALPESTRIA-1 clinical study has started with Vonafexor on Alport syndrome
• Orphan Drug Designation (ODD) granted to Vonafexor for Alport syndrome by both the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA)
• New publication: Hepatic and renal improvements with FXR agonist Vonafexor in individuals with suspected fibrotic NASH